Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
navtemadlin + cytarabine
- Development stage
- Unknown
- Lead developer
- Kartos Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
Navtemadlin + cytarabine is an investigational combination therapy being developed by Kartos Therapeutics for the treatment of acute myeloid leukemia (AML). The combination consists of navtemadlin (KRT-232), a potent and selective oral small molecule inhibitor of MDM2 (murine double minute 2), and cytarabine, a standard-of-care pyrimidine nucleoside analog chemotherapy. Navtemadlin functions by disrupting the MDM2-p53 interaction, thereby stabilizing the p53 tumor suppressor protein and inducing cell cycle arrest and apoptosis in p53-wildtype cancer cells. Cytarabine acts by inhibiting DNA polymerase and incorporating into DNA, leading to the termination of DNA strand elongation. This combination is primarily being evaluated in patients with relapsed or refractory AML and those with AML secondary to myeloproliferative neoplasms.
- Other names
- KRT-232 + cytarabineKRT-232 + low-dose cytarabinenavtemadlin + LDACKRT-232 + LDAC
02
Targets
DNA polymerase familyMDM2 (Mouse double minute 2 homolog)
Beyond the preview
Go deeper on navtemadlin + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on navtemadlin + cytarabine.